Comparison of balloon-expandable vs. self-expandable valves in patients undergoing transfemoral transcatheter aortic valve implantation: from the CENTER-collaboration by Vlastra, W. et al.
Comparison of balloon-expandable vs.
self-expandable valves in patients undergoing
transfemoral transcatheter aortic valve
implantation: from the CENTER-collaboration
Wieneke Vlastra1, Jaya Chandrasekhar1,2, Antonio J. Mu~noz-Garcia3,
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Aims The aim of this study was to compare clinical outcomes of patients undergoing transfemoral transcatheter
aortic valve implantation (TAVI) with balloon-expandable (BE) valves vs. self-expandable (SE) valves. Transcatheter
aortic valve implantation is a minimally invasive and lifesaving treatment in patients with aortic valve stenosis.
Even though BE-valves and SE-valves are both commonly used on a large scale, adequately sized trials comparing





In this CENTER-collaboration, data from 10 registries or clinical trials, selected through a systematic search, were
pooled and analysed. Propensity score methodology was used to reduce treatment selection bias and potential
confounding. The primary endpoints were mortality and stroke at 30 days follow-up in patients treated with BE-
valves compared with SE-valves. Secondary endpoints included clinical outcomes, e.g. bleeding during hospital ad-
mission. All outcomes were split for early-generation BE-valves compared with early-generation SE-valves and
new-generation BE-valves with new-generation SE-valves. The overall patient population (N = 12 381) included
6239 patients undergoing TAVI with BE-valves and 6142 patients with SE-valves. The propensity matched popula-
tion had a mean age of 81 ± 7 years and a median STS-PROM score or 6.5% [interquartile range (IQR) 4.0–13.0%].
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At 30-day follow-up, the mortality rate was not statistically different in patients undergoing TAVI with BE-valves
compared with SE-valves [BE: 5.3% vs. SE: 6.2%, relative risk (RR) 0.9; 95% confidence interval (CI) 0.7–1.0,
P = 0.10]. Stroke occurred less frequently in patients treated with BE-valves (BE: 1.9% vs. SE: 2.6%, RR 0.7; 95% CI
0.5–1.0, P = 0.03). Also, patients treated with BE-valves had a three-fold lower risk of requiring pacemaker implant-
ation (BE: 7.8% vs. SE: 20.3%, RR 0.4; 95% CI 0.3–0.4, P < 0.001). In contrast, patients treated with new-generation
BE-valves more frequently experienced major and life-threatening bleedings compared with new-generation SE-
valves (BE: 4.8% vs. SE: 2.1%, RR 2.3; 95% CI 1.6–3.3, P < 0.001).
...................................................................................................................................................................................................
Conclusion In this study, which is the largest study to compare valve types in TAVI, we demonstrated that the incidence of
stroke and pacemaker implantation was lower in patients undergoing transfemoral TAVI with BE-valves compared
with SE-valves. In contrast, patients treated with new-generation BE-valves more often suffered from major or
life-threatening bleedings than patients with new-generation SE-valves. Mortality at 30-days was not statistically dif-
ferent in patients treated with BE-valves compared with SE-valves. This study was a propensity-matched analysis
generated from observational data, accordingly current outcomes will have to be confirmed in a large scale
randomized controlled trial.
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Introduction
Transcatheter aortic valve implantation (TAVI) is a minimally invasive
and life-saving treatment in patients with severe aortic valve stenosis.1
Even though this treatment was originally developed for patients
who were considered inoperable, during the last years TAVI has
expanded from high- to intermediate-risk patients.2 Since the intro-
duction of TAVI, two valves in particular have been widely used; the
balloon-expendable (BE) Edwards SAPIEN valve (Edwards lifescien-
ces Inc., Irvine, CA, USA) and the self-expandable (SE) Medtronic
CoreValve (Medtronic Inc. Minneapolis, MN, USA).
The Edwards SAPIEN XT and consecutive Edwards SAPIEN 3 (first
in human in 2009 and 2012, respectively) valves are both composed
of three bovine pericardium leaflets mounted on a cobalt chromium
frame.3,4 These Edwards SAPIEN valves are expanded by inflation of a
balloon during rapid-pacing.5 The CoreValve system and the
CoreValve Evolut R system (first in human in 2004 and 2013, respect-
ively) consist of three porcine pericardial leaflets, mounted on a self-
expanding nitinol frame. Both devices have shown to be efficacious at
treating aortic valve stenosis with relatively low rates of long-term
complications such as paravalvular regurgitation.6,7
Accordingly, the current challenge is to further decrease the rates
in mortality, stroke, bleeding, new-onset atrial fibrillation, and need
for permanent pacemaker implantation. Even though BE and SE
valves are commonly used on a large scale, patient-level data evaluat-
ing adverse outcomes in patients treated with BE-valves compared
with SE-valves is lacking. The current available evidence includes two
modestly sized randomized controlled trials (n = 240 and n = 447)
and one propensity-matched analysis (n = 408).8–10 However, as a
consequence of the relatively low incidence of short-term complica-
tions, these studies are considered underpowered to compare indi-
vidual clinical endpoints. Therefore, in the absence of adequately
powered large randomized controlled trials, the aim of this collabora-
tive propensity-matched analysis was to compare 30-day stroke and
mortality in patients undergoing transfemoral TAVI with BE-valves vs.
SE-valves, split for early vs. new-generation valve types, in a large
study population.
Methods
Study design and population
The CENTER-trial is an international collaboration, including patients
with severe aortic valve stenosis undergoing transfemoral TAVI. The pa-
tient population of the CENTER-trial was selected through a systematic
search. Registries or trials including patients undergoing transfemoral
TAVI with either Edwards SAPIEN valves (Edwards lifesciences Inc.,
Irvine, CA, USA) or Medtronic CoreValves (Medtronic Inc. Minneapolis,
MN, USA) were invited to participate in the CENTER-collaboration.
Patients undergoing TAVI with other valve types or different access
routes than the transfemoral approach were not eligible for inclusion. All
patients provided written informed consent for the procedure and data
collection according to the policy of each participating hospital. The
CENTER-trial is registered at clinicaltrials.gov (NCT03139968).
Search strategy and study selection
We searched PubMed, Medline, and Embase for studies reporting stroke
rates in patients undergoing TAVI, published between January 2002 and
June 2017 (keywords used in the search are provided in Supplementary
material online, S1). Moreover, we identified additional articles through the
references of reviews. Studies were eligible for inclusion if they complied
with the following requirements: original studies, including patients with
aortic valve stenosis treated with transfemoral TAVI and reporting of 30-
day stroke outcomes. Moreover, in order to ensure ample operator ex-
perience in the implantation of BE- and SE-valves, the included studies had
to report on both the use of the self-expandable Medtronic CoreValve
(MCV) prosthesis and the balloon-expandable Edwards SAPIEN (ES) valve
in more than 50 patients per arm. Studies were excluded if they only
addressed patients undergoing valve-in-valve and re-do procedures or bi-
cuspid valves or addressed overlapping study population.
During the systematic search, a total of 903 individual studies were
screened by two independent reviewers (R.D. and J.v.H.). After































































































screening, 28 studies matched the inclusion and exclusion criteria
(Supplementary material online, S2), and the principle investigators of
these studies were contacted for collaboration. Of these 28 principle
investigators, 10 consented to collaboration and were included in the
CENTER-collaboration (Supplementary material online, S3). The
CENTER-collaboration consists of three national registries, two multi-
centre registries, four single-centre registries, and one randomized con-
trolled trial. Accordingly, the CENTER-collaboration includes a global
patient population with patients treated in the United States, Brazil,
Israel, and several European countries. All collaborators provided a dedi-
cated database with baseline patient characteristics, echocardiographic
data, procedural information, and follow-up data. The combined dataset
was checked for duplicate subjects, consequently, 47 duplicate patients
were removed from the final dataset. Accordingly, a total of 12 381
patients undergoing transfemoral TAVI between 2007 and 2018 with
BE- or SE-valves were included in the current patient pooled analyses.
Study endpoints
The primary endpoints of this analysis were death from any cause and stroke
in patients with BE-valves compared with SE-valves occurring within the first
30days after TAVI, as defined by the standardized definitions from the Valve
Academic Research Consortium (VARC).11–19 The OBSERVANT trial
defined stroke as a neurological deficit lasting more than 24h, or less than
24h in case of positive neuroimaging, which is equivalent to the VARC-
definition for stroke.20 Secondary outcomes included in-hospital mortality,
stroke, myocardial infarction, and major or life-threatening bleeding, as defined
by the VARC-criteria, as well as implantation of permanent pacemakers and
new-onset atrial fibrillation. Secondary outcomes compared early-generation
valve types (Edwards SAPIEN and SAPIEN XT vs. Medtronic CoreValve) and
new-generation valve-types (SAPIEN 3 vs. Evolut).
Statistical analysis
The study population was divided into two groups: patients treated with
BE- vs. SE-valves. Baseline categorical variables were presented as fre-
quencies and percentages, values of continuous variables were tested for
normal distribution and reported as mean ± standard deviation or me-
dian (25th–75th percentile) where applicable. We applied multiple im-
putation methods to estimate missing data. The imputation procedure
and subsequent multivariable regression models were performed
according to the Rubin’s protocol under the assumption that missing
data are missing at random. Propensity score methodology was used to
reduce treatment selection bias and potential confounding. The propen-
sity score was calculated using logistic regression. Baseline patient charac-
teristics that either significantly predicted the used valve-type (BE or SE),
or that correlated with the occurrence of the primary endpoints of this
study (mortality and stroke) were included in the propensity score
model. Accordingly, the propensity score included the following 12 varia-
bles: age, gender, body mass index, logistic EuroSCORE, previous myo-
cardial infarction, previous percutaneous coronary intervention (PCI),
previous stroke or transient ischaemic attack (TIA), history of peripheral
artery disease, history of atrial fibrillation, history of coronary artery dis-
ease, dyslipidaemia, and a glomerular filtration rate (GFR) of less than
30 mL/min/1.73 m2. For each patient with a BE-valve, a corresponding
comparison patient with SE-valve was selected (1:1 ratio) on the basis of
the nearest propensity score using the one-to-one nearest neighbour
method (with a caliper of 0.2 of the standard deviation of the propensity
score on the logit scale) and no replacement. We assessed the distribu-
tions of demographic data and comorbidities in the BE-valve and SE-valve
with standardized mean differences, which were calculated as a differ-
ence in means or proportions of a variable divided by a pooled estimate
of the standard deviation of that variable. A standardized mean difference
of 0.1 or less indicated a negligible difference between the means of the
two cohorts. For the primary and secondary outcomes analysis, in both
the total and the matched cohort, the incidence of the primary and sec-
ondary outcomes between BE-valve and SE-valve at 30 days was esti-
mated, with stratification by time period, using Mantel–Haenszel
weighting. The corresponding asymptotic two-sided 95% confidence
interval (CI) of the relative risk (RR) was reported. The stratification per
time period (three time periods: 2007–2010, 2011–2014, 2015–2018)
was performed since SE-valves were relatively more frequently used in
the early years of TAVI, whereas BE-valves were relatively more fre-
quently used in the recent years of TAVI (Supplementary material online,
S4). All statistical tests were two-tailed, and a P-value of <0.05 was con-
sidered statistically significant. Calculations were generated by SPSS soft-
ware (version 24.0 for Windows, SPSS, Inc., Chicago, IL, USA).
Results
Baseline characteristics of the overall
study population
A total of 12 381 patients with severe aortic valve stenosis who under-
went transfemoral TAVI with a BE-valve (n = 6239) or SE-valve
(n = 6142) were included in the CENTER-collaboration (Table 1). The
mean patient age was 82± 7 years and 58% were women. The median
STS-PROM score was 6.4% (IQR 4.0–13.0%). Patients treated with SE-
valves more frequently had a history of prior PCI and patients with BE-
valves more frequently had a prior history of peripheral artery disease.
Clinical outcomes in the overall
population
Patients treated with BE-valves less often required conversion to open
heart surgery during the TAVI procedure compared with patients
treated with SE-valves (BE: 0.8% vs. SE: 1.2%, RR 0.7; 95% CI 0.5–1.0,
P = 0.04) (Supplementary material online, S5). Moreover, patients
treated with BE-valves less frequently required permanent pacemaker
implantation (BE: 7.5% vs. SE: 20.3%, RR 0.4; 95% CI 0.3–0.4,
P < 0.001). On contrary, in-hospital major or life-threatening bleedings
were more frequently reported in patients treated with BE-valves
compared with SE-valves (BE: 6.3% vs. SE: 5.2%, RR 1.2; 95% CI 1.0–
1.4, P = 0.02). The occurrence of in-hospital mortality (BE: 4.8% vs. SE:
5.2%, RR 0.9; 95% CI 0.8–1.1, P = 0.30), stroke (BE: 1.8% vs. SE: 2.2%,
RR 0.8; 95% CI 0.6–1.1, P = 0.10), myocardial infarction (BE: 0.7% vs.
SE: 0.8%, RR 0.8; 95% CI 0.6–1.3, P = 0.42), and new-onset atrial fibril-
lation (BE: 5.3% vs. SE: 5.6%, RR 1.0; 95% CI 0.8–1.2, P = 0.67) were
comparable among both valve types. At 30-days of follow-up, mortal-
ity (BE: 5.6% vs. SE: 5.9%, RR 1.0; 95% CI 0.8–1.1, P = 0.61) and likewise
the stroke rate was comparable (BE: 2.2% vs. SE: 2.6%, RR 0.8; 95% CI
0.7–1.1, P = 0.15) among both valve-types.
Baseline characteristics of the
propensity-matched analysis
From the total CENTER patient population, a total of 4096 pairs of
patients who underwent transfemoral TAVI with a SE-valve or BE-
valve, with similar baseline demographic and clinical characteristics,
were obtained using the propensity score method (Table 1). The use
of the propensity score method generated a matched population
with a mean age of 81 ± 7 years and 57% were women. The median
STS-PROM score was 6.5% (IQR 4.0–13.0%).







































Clinical outcomes for the matched
population
In the matched population, patients treated with BE-valves less fre-
quently experienced in-hospital stroke (BE: 1.5% vs. SE: 2.3%, RR
0.6; 95% CI 0.5–0.9, P = 0.008), and likewise in-hospital mortality was
lower among patients treated with a BE-valves compared with SE-
valves (BE: 4.3% vs. SE: 5.7%, RR 0.8; 95% CI 0.6–0.9, P = 0.009)
(Table 2, Figure 1). Moreover, patients treated with BE-valves had a
three-fold lower risk of permanent pacemaker implantation (BE:
7.8% vs. SE: 20.3%, RR 0.4; 95% CI 0.3–0.4, P < 0.001). On contrary,
there was a trend to in-hospital major or life-threatening bleedings
more frequently occurring in patients treated with BE-valves com-
pared with SE-valves (BE: 6.6% vs. SE: 5.5%, RR 1.2; 95% CI 1.0–1.4,
P = 0.07). Rates of conversion to open heart surgery (BE: 0.6% vs. SE:
1.2%, RR 0.7; 95% CI 0.4–1.1, P = 0.10), in-hospital myocardial infarc-
tion (BE: 0.6% vs. SE: 0.7%, RR 0.9; 95% CI 0.5–1.6, P = 0.72), and
new-onset atrial fibrillation (BE: 5.6% vs. SE: 5.5%, RR 1.0; 95% CI
1.3–0.8, P = 0.97) were not different among the two valve types. At
30-days follow-up, the stroke rate remained significantly lower in
patients treated with BE valves (BE: 1.9% vs. SE: 2.6%, RR 0.7; 95% CI
0.5–1.0, P = 0.03). The lower rate of stroke in patients treated with
BE-valves compared with SE-valves was consistent among proce-
dures performed in the early years of TAVI and those in more re-
cent years (Supplementary material online, S4) and likewise among
nine out of ten collaborating studies (Supplementary material online,
S6). Of patients treated with a BE-valve who suffered from stroke
after TAVI, 13.7% died during hospital admission, compared with
26.3% of the patients treated with SE-valves suffering from stroke
(P = 0.09). In-hospital mortality was considerably higher in stroke
patients (odds ratio 5.5, 95% CI 3.6–8.5). Mortality at 30 days follow-
up was comparable among both valve types (BE: 5.3% vs. SE: 6.2%,
RR 0.9; 95% CI 0.7–1.0, P = 0.10).
Clinical outcomes split for early-
generation valves and new-generation
valves
Clinical outcomes were compared between patients undergoing
transfemoral TAVI with early-generation Edwards SAPIEN (ES) and
SAPIEN XT (XT) BE-valves vs. early-generation Medtronic
CoreValve (MCV) SE-valves, and likewise new-generation SAPIEN 3
........................................................................... ...........................................................................
....................................................................................................................................................................................................................
Table 1 Baseline patient characteristics of the overall population and propensity matched cohort
Overall patient population Propensity matched population
BE (n 5 6239) SE (n 5 6142) SMD BE (n 5 4096) SE (n 5 4096) SMD
Demographics
Age (years) 81.7 ± 6.9 81.2 ± 7.1 0.071 81.5 ± 7.1 81.3 ± 7.1 0.028
Female gender 3700 (59) 3420 (56) 0.081 2364 (58) 2336 (57) 0.015
Body mass index (kg/m2) 27.0 ± 4.8 27.3 ± 4.9 0.062 27.2 ± 4.8 27.1 ± 4.8 0.021
Medical history
Previous CVA or TIA 660 (11) 631 (10) 0.018 420 (10) 436 (11) 0.023
Previous MI 815 (13) 855 (14) 0.041 558 (14) 574 (14) 0.018
Previous PCI 1239 (20) 1421 (23) 0.107 883 (22) 886 (22) 0.002
Previous CABG 728 (12) 745 (12) 0.024 497 (12) 511 (13) 0.018
Diabetes mellitus 1952 (31) 1924 (31) 0.043 1298 (32) 1293 (32) 0.003
Hypertension 4920 (79) 4815 (78) 0.015 3223 (79) 3231 (79) 0.006
Dyslipidaemia 3383 (54) 3410 (56) 0.029 2236 (55) 2247 (55) 0.007
Peripheral artery disease 992 (16) 816 (13) 0.116 588 (14) 599 (15) 0.012
Coronary artery disease 2552 (41) 2530 (41) 0.007 1668 (41) 1682 (41) 0.009
Atrial fibrillation 1764 (28) 1590 (26) 0.071 1087 (27) 1115 (27) 0.019
GFR<30 mL/min 855 (14) 827 (14) 0.011 565 (14) 574 (14) 0.011
Logistic EuroSCORE (%) 15.2 (10.0–23.1) 14.6 (9.0–22.7) 0.055 15.0 (9.7–23.0) 15.0 (9.3–23.3) 0.018
STS-PROM (%) 6.4 (4.0–13.9) 6.4 (3.9–12.3) 0.082 6.3 (4.0–14.4) 6.6 (4.0–12.8) 0.051
Aortic mean gradient 51.1 ± 17.5 51.0 ± 17.2 0.006 51.0 ± 17.6 51.1 ± 17.4 0.006
Implanted valvesa n ¼ 5739 n = 5910 n = 3764 n = 3937
Edwards Sapien 474 (8) 313 (8)
Sapien XT 3552 (62) 2329 (62)
Sapien 3 1713 (30) 1122 (30)
CoreValve 4240 (72) 2846 (72)
Evolut 1670 (28) 1091 (28)
A standardized mean difference of 0.1 or less indicated a negligible difference between the means of the two cohorts.
GFR: glomerular filtration rate; SMD, standardized mean difference; TIA: transient ischaemic attack.
aThe exact valve type was unknown for patients included in the BRAVO3 study (6%).





















.(S3) BE-valves vs. new-generation SE-valves (Evolut series) (Table 3,
Figure 2). Patients treated with new-generation BE-valves had a four-
fold lower risk of conversion to open heart surgery during the TAVI
procedure than patients treated with new-generation SE-valves (S3:
0.7% vs. Evolut: 2.6%, RR 0.3; 95% CI 0.2–0.4, P < 0.001). Moreover,
in-hospital mortality was lower in patients treated with early-
generation BE-valves compared with early-generation SE-valves (ES:
6.8 and XT: 5.1% vs. MCV: 6.8%, RR 0.8; 95% CI 0.7–0.9, P = 0.003).
In contrast, the rate of 30-day mortality was comparable in patients
treated with early-generation BE-valves and early-generation SE-
valves (ES: 9.1% and XT: 5.9% vs. MCV: 7.1%, RR 0.9; 95% CI 0.8–1.0,
P = 0.11). Mortality in new-generation valves was comparable both
during hospital admission (S3: 2.4% vs. Evolut: 3.1%, RR 0.8; 95% CI
0.5–1.1, P = 0.14) and at 30-day follow-up (S3: 3.1% vs. Evolut: 3.4%,
RR 0.9; 95% CI 0.6–1.3, P = 0.73). Patients treated with new-
generation BE-valves less frequently suffered from stroke both during
hospital-admission (S3: 0.8% vs. Evolut: 2.8%, RR 0.3; 95% CI 0.2–0.5,







Comparing outcomes in paents treated with BE-valves vs SE-valves
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Figure 1 Clinical outcomes in patients treated with balloon-expandable valves compared with self-expandable valves.
....................................................................................................................................................................................................................
Table 2 Outcomes in the propensity matched population (N 5 8192)
BE (n 5 4096) SE (n 5 4096) Relative risk (95% CI) P-value
Procedural
Conversion to open heart surgery 21 (0.6%) 47 (1.2%) 0.7 (0.4–1.1) 0.10
During hospital admission
Mortality 150 (4.3%) 206 (5.7%) 0.8 (0.6–0.9) 0.009
Stroke 56 (1.5%) 89 (2.3%) 0.6 (0.5–0.9) 0.008
Myocardial infarction 24 (0.6%) 27 (0.7%) 0.9 (0.5–1.6) 0.72
Major or life-threatening bleeding 232 (6.6%) 197 (5.5%) 1.2 (1.0–1.4) 0.07
New-onset atrial fibrillation 116 (5.6%) 73 (5.5%) 1.0 (0.8–1.3) 0.97
Permanent pacemaker implantation 270 (7.8%) 753 (20.3%) 0.4 (0.3–0.4) <0.001
At 30 days
Mortality 184 (5.3%) 237 (6.2%) 0.9 (0.7–1.0) 0.10
Stroke 65 (1.9%) 98 (2.6%) 0.7 (0.5–1.0) 0.03
Incidence and relative risk (95% confidence interval) of clinical outcomes in patients treated with BE-valves compared with SE-valves, stratified by time period, analysed using
the Mantel–Haenszel method. Reporting of secondary outcomes was not an inclusion criteria, and accordingly was not always documented by collaborating studies. Conversion
to open heart surgery was complete in 92%, in-hospital mortality in 87%, stroke in 94%, myocardial infarction in 94%, major or life-threatening bleeding in 87%, new-onset atrial
fibrillation in 42%, and permanent pacemaker implantation in 88%.


































..0.4; 95% CI 0.2–0.6, P < 0.001) compared with patients treated with
new-generation BE-valves. The stroke rate in early-generation valves
was comparable during hospital admission (ES: 1.6% and XT: 1.7% vs.
MCV: 2.1%, RR 0.8; 95% CI 0.6–1.1, P = 0.15) and at 30-day follow-up
(ES: 1.7% and XT: 2.1% vs. MCV: 2.3%, RR 0.9; 95% CI 0.7–1.1,
P = 0.30). Patients undergoing TAVI with new-generation BE-valves
more frequently encountered major or life-threatening bleedings
compared with patients treated with new-generation SE-valves (S3:
4.8% vs. Evolut: 2.1%, RR 2.3; 95% CI 1.6–3.3, P < 0.001). On contrary,
the rate of major and life-threatening bleeding in early-generation
valves was comparable (ES: 2.6% and XT: 5.1% vs. MCV: 5.2%, RR 0.9;
95% CI 0.8–1.1, P = 0.35). Patients undergoing TAVI with new-
generation BE-valves less frequently required permanent pacemaker
implantation compared with patients treated with new-generation
SE-valves (S3: 8.9% vs. Evolut: 18.1%, RR 0.5; 95% CI 0.4–0.6,
P < 0.001), this difference was larger in patients treated with early-
generation valves (ES: 6.1% and XT: 7.5% vs. MCV: 21.2%, RR 0.3;
95% CI 0.3–0.4, P < 0.001).
Discussion
The main finding of the current large scale, propensity-matched study
was that the stroke rate was lower in patients undergoing transfe-
moral TAVI with BE-valves compared with SE-valves. Additionally,
patients treated with a BE-valve had a three-fold lower risk of requir-
ing permanent pacemaker implantation. There was no difference in
30-day mortality rates between both valve types. In contrast, patients
treated with new-generation BE-valves more often suffered from
major or life-threatening bleedings than patients with new-
generation SE-valves.
Description of the study results
Patients treated with early-generation SE-valves frequently needed
pacemaker implantation in 21.2% of the cases, this rate reduced in
new-generation SE-valves to 18.1%, but remained considerably
higher compared with new-generation BE-valves (8.9%, P < 0.001).
The high rate of permanent pacemaker implantation in patients
....................................................................................................................................................................................................................
Table 3 Outcomes split for early-generation and new-generation valves
BE (n 5 3764) SE (n 5 3937) Relative risk (95% CI) P-value
Procedural
Conversion to open heart surgery Total: 31 (0.9%) Total: 47 (1.2%) 0.7 (0.4–1.1) 0.10
ES: 2 (0.6%)/XT: 22 (1.0%) MCV: 20 (0.7%) 1.3 (0.9–2.0) 0.21
S3: 7 (0.7%) Evolut: 27 (2.6%) 0.3 (0.2–0.4) <0.001
During hospital admission
Total: 142 (4.4%) Total: 206 (5.7%) 0.8 (0.6–1.0) 0.02
Mortality ES: 21 (6.8%)/XT: 98 (5.1%) MCV: 163 (6.8%) 0.8 (0.7–0.9) 0.003
S3: 23 (2.4%) Evolut: 32 (3.1%) 0.8 (0.5–1.1) 0.14
Stroke Total: 50 (1.4%) Total: 85 (2.3%) 0.6 (0.5–0.9) 0.008
ES: 5 (1.6%)/XT: 37 (1.7%) MCV: 56 (2.1%) 0.8 (0.6–1.1) 0.15
S3: 8 (0.8%) Evolut: 29 (2.8%) 0.3 (0.2–0.5) <0.001
Myocardial infarction Total: 23 (0.7%) Total: 25 (0.7%) 1.0 (0.6–1.7) 0.97
ES: 2 (0.6%)/SXT: 17 (0.8%) MCV: 20 (0.7%) 1.0 (0.6–1.6) 0.90
S3: 4 (0.4%) Evolut: 5 (0.5%) 0.8 (0.3–2.1) 0.69
Major or life-threatening bleeding Total: 154 (4.8%) Total: 147 (4.3%) 1.1 (0.9–1.4) 0.34
ES: 8 (2.6%)/XT: 102 (5.1%) MCV: 126 (5.2%) 0.9 (0.8–1.1) 0.35
S3: 44 (4.8%) Evolut: 21 (2.1%) 2.3 (1.6–3.3) <0.001
New onset atrial fibrillation Total: 103 (5.5%) Total: 63 (5.4%) 1.1 (0.8–1.5) 0.52
ES: 15 (7.0%)/XT: 73 (6.0%) MCV: 59 (5.6%) 1.1 (0.8–1.4) 0.42
S3: 15 (4.4%) Evolut: 4 (3.7%) 1.2 (0.6–2.5) 0.67
Permanent pacemaker implantation Total: 270 (7.8%) Total: 753 (20.3%) 0.4 (0.3–0.4) <0.001
ES: 19 (6.1%)/XT: 162 (7.5%) MCV: 567 (21.2%) 0.3 (0.3–0.4) <0.001
S3: 89 (8.9%) Evolut: 186 (18.1%) 0.5 (0.4–0.6) <0.001
At 30 days
Mortality Total: 175 (5.6%) Total: 223 (6.2%) 0.9 (0.7–1.1) 0.24
ES: 27 (9.1%)/XT: 124 (5.9%) MCV: 191 (7.1%) 0.9 (0.8–1.0) 0.11
S3: 24 (3.1%) Evolut: 32 (3.4%) 0.9 (0.6–1.3) 0.73
Stroke Total: 58 (1.8%) Total: 93 (2.6%) 0.7 (0.5–1.0) 0.04
ES: 5 (1.7%)/XT: 43 (2.1%) MCV: 62 (2.3%) 0.9 (0.7–1.1) 0.30
S3: 10 (1.3%) Evolut: 31 (3.3%) 0.4 (0.2–0.6) <0.001
Incidence and relative risk (95% confidence interval). Early generation valves: Edwards SAPIEN (ES), SAPIEN XT (XT) vs. Medtronic CoreValve (MCV). New-generation valves:
SAPIEN 3 valve (S3) vs. Evolut series (Evolut). In the BRAVO-3 study, the exact valve type was not recorded, these patients are excluded from the current analysis.
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Figure 2 Clinical outcomes in patients treated with early-generation balloon-expandable valves compared with early-generation self-expandable
valves, and new-generation balloon-expandable valves compared with new-generation self-expandable valves.













































.treated with SE-valves has previously been documented.21 However,
in our study population we also found higher rates of in-hospital mor-
tality as well as 30-day stroke in patients who underwent TAVI with a
SE-valve. The higher stroke rate in SE-valves compared with
BE-valves was mainly powered by the new-generation valves, which
highlights the importance of this finding. We hypothesize that the
working mechanism of the implantation of SE-valves may generate
the higher observed procedural stroke rate. SE-valves are implanted
slowly, and stepwise and have the option to reposition the prosthesis
before final implantation, accordingly the longer implantation time
may increase the likelihood of embolization of particles of the native
calcified valve, when compared with the rather rapid positioning of
BE-valves. Also the surface of the SE-valve systems is larger com-
pared with BE-valves, this may generate more extensive manipulation
of the often calcified aortic arch. This is in accordance with a study
from Erdoes et al.,22 which quantified the amount of cerebral embol-
ization during TAVI, by performing transcranial Doppler recordings
during 44 TAVI procedures. There was a 41% higher rate of high-
intensity transient signals, representing cerebral embolization, in
patients treated with SE-valves compared with BE-valves (P = 0.02).
Cerebral embolization was higher both during and after valve-
deployment in patients treated with SE-valves. Likewise, a recent his-
topathologic assessment of captured debris derived from cerebral
protection devices from 246 TAVI procedures, showed that in
patients treated with SE-valves, more frequently larger particles were
captured compared with those treated with BE-valves.23 The higher
in-hospital mortality rate in patients treated with SE-valves may be
the consequence of this higher procedural stroke rate. Patients with
stroke after TAVI had a 5.5-fold higher chance to die during hospital
admission. Also, the mortality rate in patients treated with SE-valves
suffering from stroke was higher compared with patients treated
with BE-valves suffering from stroke. Moreover, the trend to a higher
rate of emergency surgery in patients treated with SE-valves may also
have contributed to the higher in-hospital mortality rate among
patients treated with SE-valves. Lastly, in this study patients treated
with new-generation BE-valves more frequently experienced in-
hospital major or life-threatening bleedings compared with patients
treated with new-generation SE-valves. The early-generation
Edwards SAPIEN valve required large sheath sizes (22F/24F), how-
ever, the new-generation SAPIEN 3 requires smaller sheath sizes
(14F/16F), this is similar to the Evolut-series. Accordingly, this finding
is subject to further research.
Comparison with the literature
To our knowledge, there are three earlier clinical studies providing a
head-to-head comparison of patients treated with BE-valves com-
pared with SE-valves. The PRAGMATIC collaboration was also an
international propensity-matched analysis, including patients from
multiple centres (n = 408).9 In the PRAGMATIC collaboration, the
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with SE-valves (RR 4.6; 95% CI 2.4–9.1, P < 0.001). Similar to this
study, rates of 30-day mortality (SE: 8.8% vs. BE: 6.4%, RR 1.4; 95% CI
0.7–3.0, P = 0.35) and stroke (SE: 2.9% vs. BE: 1.0%, RR 3.1; 95% CI
0.6–15.4, P = 0.17) were numerically slightly higher in patients treated
with SE-valves. However, due to the modest sample size of the
PRAGMATIC study, the study was underpowered to detect statistic-
al significant differences in these relatively rare outcomes. Moreover,
in the PRAGMATIC collaboration studies were not selected through
a systematic review, accordingly it is unclear if collaborating centres
had experience with both valve types, this may have resulted in a
comparison of clinical outcomes between centres rather than valve-
types.
The CHOICE-trial (n = 240) was a randomized study that con-
cluded there was a lower rate of device success in SE-valves com-
pared with BE-valves (78% vs. 96%, P < 0.001), as a consequence of
more frequent aortic regurgitation in patients treated with SE-valves.8
Aortic regurgitation, even when defined as mild, is associated with a
three-fold higher mortality risk.24,25 The CHOICE-trial also found
that pacemaker implantation occurred more frequently in patients
treated with SE-valves. The SOLVE-TAVI (n = 447) was a recent
randomized controlled trial evaluating BE vs. SE-valves.10 The com-
bined primary endpoint of mortality, stroke, regurgitation and per-
manent pacemaker implantation was comparable in both arms (BE:
26.1% vs. SE: 27.2%, Pequivalence = 0.02). However, this combined end-
point was mainly powered by the rate of pacemaker implantation,
which was high in both arms (BE: 19.0% vs. SE: 22.9%, P = 0.34), sug-
gesting a possible learning curve in the implantation of the SAPIEN 3
valve. In contrast to this study, there was a higher number of stroke
in the patients treated with BE-valves (BE: 4.7% vs. SE: 0.5%, P = 0.01).
However, due to the relative low incidence of stroke and mortality,
all three trials were underpowered to assess these individual
endpoints.
Current device developments and future
perspectives
Both Edwards Lifesciences and Medtronic Cardiovascular continue
to develop new valves in order to further reduce clinical complica-
tions. First results suggest that implantation of these new devices are
associated to a lower pacemaker implantation rate. The self-
expanding Evolut series (now joined by the EVOLUT-R and the
EVOLUT-Pro valves) are the newest developments of Medtronic
Cardiovascular. Pacemaker implantation in patients treated with the
EVOLUT-R was lower (16.4%) compared with earlier self-expanding
valves.7 The CENTERA is a new, self-expanding valve from Edwards
Lifesciences that allows repositionability of the valve prior to the final
implantation. In the pivotal trial in high-risk patients (n = 203), new
pacemaker implantation was required in a mere 4.5%.26 Accordingly,
in this first trial, this novel self-expanding valve showed four-fold
lower pacemaker implantation rate compared with the self-
expandable valves in this study, and also a two-fold lower pacemaker
implantation rate compared with balloon-expandable valves. With
the expansion of TAVI to low-risk patients, the reduction of stroke
and mortality will become even more important. Currently, the new-
est devices of both Edwards Lifesciences (PARTNER 3,
NCT02675114) and Medtronic Cardiovascular (NCT02701283) are
both studied in low-risk patients in large scale randomized controlled
trials. The results of these trials will tell us more about clinical out-
comes of the newest generation of valves. However, we believe this
study warrants a dedicated large scale randomized trial.
Study limitations
This study was a propensity-matched analysis, generated from real-
world observational data. However, even though the populations of
the current collaboration were selected through a systematic-search,
the willingness of principle investigators to collaborate may be the re-
sult of preconceived beliefs about the optimal therapy and this may
have influenced the final study population. Moreover, due to the non-
randomized nature of this study, the results are subject to selection
bias and confounding. Even though propensity-score matching was
performed in an aim to minimize these biases, hidden bias may remain
due to the influences of unmeasured confounders. Moreover, pro-
pensity matching may increase the heterogeneity due to strengthen-
ing of unmeasured confounders. Furthermore, in this collaboration,
many participating studies did not have independent adjudication
committees, which may have resulted in potential reporting bias,
however we do not expect this to have a relation with a certain valve
type. Also, in this study, aortic regurgitation after TAVI was not avail-
able as an outcome, accordingly we cannot compare differences in
aortic regurgitation between different valve-types. Finally, this study
focused on short-term clinical complications, accordingly, conclu-
sions on valve durability or long-term outcomes cannot be made.
Supplementary material
Supplementary material is available at European Heart Journal online.
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